Physician profile
Jack Rostas
NPI 1902063282
$1,750.04
in general payments reported to CMS, 2019-2025
19 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $19.06 · 2022: $305 · 2023: $314 · 2024: $352 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Travel and Lodging: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.42 |
| Travel and Lodging | $193.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $315.80 | 2022-2025 | 1788, Spy-Phi System, Molli |
| Intuitive Surgical, INC. | $300.08 | 2022-2025 | |
| Endomagnetics Ltd | $152.27 | 2023-2024 | Magseed, Magtrace |
| Davol INC. | $142.30 | 2019-2022 | |
| Integra Lifesciences Corporation | $139.28 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ethicon US, LLC | $115.80 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $108.97 | 2024-2025 | Calquence, Lynparza |
| Janssen Biotech, INC. | $87.11 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Jazz Pharmaceuticals INC. | $66.89 | 2025 | |
| Novartis Pharmaceuticals Corporation | $62.73 | 2025 | |
| Daiichi Sankyo INC. | $53.04 | 2024-2025 | Datroway, Enhertu |
| Angiodynamics, INC. | $46.26 | 2023 | Nanoknife |
| Incyte Corporation | $41.74 | 2025 | Jakafi, Pemazyre, Monjuvi |
| Servier Pharmaceuticals LLC | $24.60 | 2024 | |
| Genentech USA, INC. | $23.29 | 2024 | Polivy, Lunsumio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $21.89 | 2024 | Epkinly |
| Tela Bio, INC. | $19.06 | 2021 | |
| Biocomposites INC | $17.25 | 2025 | Stimulan |
| Boston Scientific Corporation | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Rostas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.